HK Stock Market Move | JACOBIO-B(01167) increased by over 4%, the company released research data on the combination of SHP2 inhibitors, Gorelinsai is about to be listed

JACOBIO-B (01167) rose by over 4%, reaching a 4.78% increase to HK$4.38 as of the time of publication, with a trading volume of HK$15.5862 million. On the news front, JAKOSSI announced that its independently developed SHP2 inhibitor sitneprotafib (JAB-3312) related research was published in Clinical Cancer Research, revealing preclinical and clinical data on the combination therapy of SHP2 inhibitors with PD-1 antibodies and targeted RTK/RAS/MAPK pathways, as well as representative patient cases responsive to the combination therapy. The company is currently conducting a Phase III clinical trial of sitneprotafib in combination with Golariseb, marking sitneprotafib as the first SHP2 inhibitor to enter Phase III clinical trials worldwide. Pacific Securities previously noted that the company is expected to submit an application for the second-line treatment of KRAS G12C+ non-small cell lung cancer with Golariseb in May 2024, with expected approval and receipt of a research milestone fee in Q2 2025. Based on safety advantages (Grade 3 TRAE lower than competitors) and the sales advantage of partner Shanghai Allist Pharmaceuticals Co., Ltd. in lung cancer, the firm predicts a sales peak of 1.1 billion yuan for Golariseb. Additionally, Phase III trials for first-line non-small cell lung cancer and pancreatic/pancancer have begun for Golariseb, with enrollment completion expected in H2 2026.